Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.30 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28614043 | 0.90 | KDM4E (0.36) | KDM4EPOLBL3MBTL1CA1CA2 | |
| SCHEMBL11739358 | 0.90 | KDM4E (0.36) | KDM4EPOLBL3MBTL1CA1CA2 | |
| SCHEMBL30609955 | 0.84 | KDM4E (0.36) | KDM4EPOLBL3MBTL1CA1CA2 | |
| SCHEMBL11297752 | 0.81 | KDM4E (0.35) | KDM4EPOLBL3MBTL1KMT2A | |
| SCHEMBL3444734 | 0.79 | KDM4E (0.33) | KDM4EPOLBL3MBTL1 | |
| SCHEMBL8966171 | 0.79 | KDM4E (0.30) | KDM4EPOLBL3MBTL1 | |
| SCHEMBL10929891 | 0.79 | — | — | |
| Methyl Alcohol SCHEMBL16238245 | 0.77 | KDM4E (0.33) | KDM4EPOLBL3MBTL1KMT2A | |
| SCHEMBL8177761 | 0.75 | KMT2A (0.45) | KMT2ACA1CA2CA4 | |
| SCHEMBL28591476 | 0.75 | NOS3 (0.32) | NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 819 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814563-B2 | Bioreachable chiral dopants for liquid crystal applications | ZYMERGEN INC. (US) | 2023-11-14 | — | — | US | claimed |
| US-20230203378-A1 | FORMULATIONS OF BIOREACHABLE DOPANTS FOR LIQUID CRYSTALS | KENT STATE UNIVERSITY | 2023-06-29 | — | — | US | claimed |
| US-20220025267-A1 | BIOREACHABLE CHIRAL DOPANTS FOR LIQUID CRYSTAL APPLICATIONS | ZYMERGEN ACQUISITION SUB, INC. | 2022-01-27 | — | — | US | claimed |
| EP-3891252-A2 | BIOREACHABLE CHIRAL DOPANTS FOR LIQUID CRYSTAL APPLICATIONS | Zymergen Inc. (US) | 2021-10-13 | — | — | EP | claimed |
| US-6602562-B2 | High dielectric anisotropy and clearing point with little impact on voltage holding ratio, low temperature stability and response time | MERCK PATENT GESELLSCHAFT MIT (DE) | 2003-08-05 | — | — | US | claimed |
| US-20030113482-A1 | Realignment layer; field has a component parallel to the liquid-crystal layer; positive dielectric anisotropy | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2003-06-19 | — | — | US | claimed |
| US-6217792-B1 | Chiral dopants | MERCK PATENT GMBH (DE) | 2001-04-17 | — | — | US | claimed |
| EP-0408995-B1 | Liquid crystal medium with limited temperature-dependence of the d/p coefficient | MERCK PATENT GMBH (DE) | 1995-11-08 | — | — | EP | claimed |
| US-5139698-A | Achiral liquid crystal compound with doping component | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1992-08-18 | — | — | US | claimed |
| EP-0408995-A2 | Liquid crystal medium with limited temperature-dependence of the d/p coefficient | MERCK PATENT GmbH (DE) | 1991-01-23 | — | — | EP | claimed |
| US-11814563-B2 | Bioreachable chiral dopants for liquid crystal applications | ZYMERGEN INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230203378-A1 | FORMULATIONS OF BIOREACHABLE DOPANTS FOR LIQUID CRYSTALS | KENT STATE UNIVERSITY | 2023-06-29 | — | — | US | disclosed |
| US-11667841-B2 | Dibenzofuran and dibenzothiophene derivatives | MERCK PATENT GMBH (DE) | 2023-06-06 | — | — | US | disclosed |
| CN-109627658-B | Composition comprising functionalized polyvinyl alcohol and nanocapsules containing a liquid crystalline medium | 默克专利股份有限公司 | 2023-02-17 | — | — | CN | disclosed |
| EP-3638657-B1 | DIBENZOFURAN DERIVATIVES AND DIBENZOTHIOPHENE DERIVATIVES | MERCK PATENT GMBH (DE) | 2022-07-20 | — | — | EP | disclosed |
| WO-1989008637-A1 | DERIVATIVES OF 2,3-DIFLUOROHYDROQUINONE | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1989-09-21 | — | — | WO | disclosed |
| WO-1989008649-A1 | HETEROCYCLIC 1,2-DIFLUOROBENZENE DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1989-09-21 | — | — | WO | disclosed |
| EP-0332024-A1 | Heterocyclic derivatives of 1,2-difluorobenzene | MERCK PATENT GmbH (DE) | 1989-09-13 | — | — | EP | disclosed |
| EP-0332007-A1 | Derivatives of 2,3-difluorohydroquinone | MERCK PATENT GmbH (DE) | 1989-09-13 | — | — | EP | disclosed |
| US-4433100-A | DICYCLOPENTADIENE, NON-AROMATIC UNSATURATED HYDROCARBON, FATTY OR ROSIN ACID | NEVILLE CHEMICAL COMPANY (US) | 1984-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667841-B2 | Dibenzofuran and dibenzothiophene derivatives | DDT, MYT1, DBF4 | KDM4E 3877/4885POLB 3769/4885L3MBTL1 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.